Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s62. https://doi.org/10.25251/skin.6.supp.62